A pharmacological inhibitor of SGLT2 (sodium-glucose co-transporters inhibitor) has been evaluated as a useful drug for the treatment of obesity, diabetes, and hypertension with no significant toxic effects (9). This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.